BMEA241220P25000
- 0.00
- 0.000.00%
Biomea Fusion Newsroom
Biomea Fusion Advances Diabetes Treatment With Positive Study Results
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Biomea Fusion Price Target Lowered to $50 From $60 at Oppenheimer
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
Biomea Stock Sinks 16% After Phase 2 Data Release
Express News | Biomea Fusion Shares Are Trading Lower. The Company Reported Phase II Results for Icovamenib in Type 2 Diabetes
Biomea Fusion Announces Results From Ongoing COVALENT-111 Study
Express News | Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
What's Driving Biomea Fusion? Stock Soars 25%
Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
Express News | HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target
Biomea Fusion's Innovative Diabetes Therapy Boosts Buy Rating With Promising Preclinical Data on Icovamenib
Express News | Biomea Fusion Says In Preclinical Experiments, Icovamenib Enhanced Beta Cell Function And Responsiveness Of Human Islets To GLP-1-Based Therapies
Express News | Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
Biomea Fusion Slides As Insider Purchases Lose Another US$26k